Standard BioTools Inc. (NASDAQ:LAB – Get Free Report) was up 7% during mid-day trading on Wednesday . The company traded as high as $1.65 and last traded at $1.62. Approximately 692,280 shares changed hands during trading, a decline of 72% from the average daily volume of 2,460,480 shares. The stock had previously closed at $1.51.
Analysts Set New Price Targets
Separately, TD Cowen reduced their target price on shares of Standard BioTools from $2.75 to $2.50 and set a “buy” rating for the company in a research note on Thursday, October 31st.
Read Our Latest Stock Analysis on Standard BioTools
Standard BioTools Price Performance
Insider Activity at Standard BioTools
In other Standard BioTools news, Director Casdin Partners Master Fund, L acquired 150,000 shares of the stock in a transaction dated Monday, August 26th. The shares were acquired at an average cost of $2.15 per share, for a total transaction of $322,500.00. Following the completion of the transaction, the director now directly owns 53,775,821 shares of the company’s stock, valued at approximately $115,618,015.15. The trade was a 0.28 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 53.10% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Standard BioTools
Hedge funds have recently bought and sold shares of the business. Arizona State Retirement System grew its stake in shares of Standard BioTools by 16.6% during the second quarter. Arizona State Retirement System now owns 69,596 shares of the company’s stock worth $123,000 after acquiring an additional 9,933 shares during the last quarter. XTX Topco Ltd lifted its position in shares of Standard BioTools by 38.2% in the second quarter. XTX Topco Ltd now owns 35,965 shares of the company’s stock valued at $64,000 after acquiring an additional 9,947 shares in the last quarter. Victory Capital Management Inc. grew its position in shares of Standard BioTools by 27.3% in the second quarter. Victory Capital Management Inc. now owns 46,967 shares of the company’s stock valued at $83,000 after purchasing an additional 10,067 shares in the last quarter. Freestone Capital Holdings LLC purchased a new position in Standard BioTools in the first quarter worth approximately $31,000. Finally, Wolverine Trading LLC purchased a new stake in Standard BioTools in the third quarter valued at approximately $27,000. Institutional investors own 53.74% of the company’s stock.
Standard BioTools Company Profile
Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.
See Also
- Five stocks we like better than Standard BioTools
- Stock Sentiment Analysis: How it Works
- Target Results Are Not a Retail Bellwether: Why the Dip Is a Buy
- Consumer Staples Stocks, Explained
- Williams-Sonoma Stock: Buy It and Never Let It Go
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- 5 Dividend ETFs to Buy and Hold Forever
Receive News & Ratings for Standard BioTools Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Standard BioTools and related companies with MarketBeat.com's FREE daily email newsletter.